• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Oral azacytidine maintenance therapy improved survival outcomes in patients with acute myeloid leukemia

byRicha SharmaandDeepti Shroff Karhade
January 24, 2021
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Oral azacytidine also known as CC-486 has been found to improve survival outcomes in patients with acute myeloid leukemia.

2. Frequently reported adverse events associated with oral azacytidine maintenance therapy were nausea, vomiting and diarrhea. However, the frequency of these events reduced with ongoing treatment cycles as a possible result of dose adjustment and medication initiation.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Acute myeloid leukemia (AML) is predominantly present in the elderly population although treated with chemotherapy, often results in relapse and reduced survival. This randomized, double-blind, placebo-control trial was conducted to assess overall survival and adverse effects of CC-486 as a maintenance therapy in patients with AML. Participants were recruited and randomized into one of two groups. The first group received oral azacytidine (CC-486) and the second group received a placebo. Participants were monitored until death, or if consent was withdrawn, or if loss to follow-up occurred. The most common adverse events as a result of CC-486 or placebo administration were nausea, vomiting and diarrhea. The study showed a significant difference and longer relapse-free survival period in the treatment group when compared to the placebo group. The study was strengthened by its large sample size and can be generalized to the larger patient population.

Click to read the study in NEJM

Relevant Reading: Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia

In-Depth [randomized controlled trial]: This phase 3 trial was conducted across 23 countries at 148 sites from May 2013 to October 2017 with a data cutoff date of July 2019. Patient eligibility was determined using the following: over 55 years of age, new diagnosis of acute myeloid leukemia or a secondary diagnosis of AML or a poor-risk associated with the diagnosis of AML and have received chemotherapy and in remission at time of screening. A total of 472 patients were enrolled and randomized into the treatment group where they received 300 mg of CC-486 or into the placebo group. A total of 245 were male and 227 were female participants of which the median age was 68 years. The treatment was administered once a day for fourteen days and the cycle was repeated every 28 days. Ongoing adverse events were noted throughout the follow up period and laboratory assessments were conducted for the first 24 cycles for every 3 cycles and the dosing regimen was modified based on the results. The calculated power of the study was 90% based on a total enrollment of 460 patients. The study had a dropout rate of 5% and a 60-month average trial duration. The placebo group overall survival time was 14.8 months compared to the CC-486 group for which it was 24.7 months and the median duration of the treatment was 6 cycles versus 12 cycles respectively. Both groups demonstrated similar adverse events (i.e.; gastrointestinal including nausea, vomiting and diarrhea) as a result of treatment. Neutropenia and thrombocytopenia were also reported as a result of treatment in both groups. In conclusion, both groups demonstrated similar adverse events, however there was a longer relapse-free survival period as a result of oral azacytidine maintenance therapy.

RELATED REPORTS

#VisualAbstract: Early mobilization after ICU mechanical ventilation does not improve survival

Early mobilization after ICU mechanical ventilation does not improve survival

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article

Tags: acute myeloid leukemia (AML)azacytidinesurvival
Previous Post

#VisualAbstract Oral poly(ADP-ribose) polymerase inhibitors were associated with an increased risk of myelodysplastic syndrome and acute myeloid leukaemia over placebo treatment in patients with cancer

Next Post

Focused ultrasound subthalamotomy revealed improvement in Parkinson’s patients

RelatedReports

#VisualAbstract: Early mobilization after ICU mechanical ventilation does not improve survival
StudyGraphics

#VisualAbstract: Early mobilization after ICU mechanical ventilation does not improve survival

December 1, 2022
ICU chlorhexidine baths do not reduce rates of hospital-acquired infections
Chronic Disease

Early mobilization after ICU mechanical ventilation does not improve survival

November 22, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Obstetrics and Gynecology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

September 16, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Neurology Classics

The ISAT trial: endovascular coiling superior to neurosurgical clipping in selected patients with aneurysmal subarachnoid hemorrhage [Classics Series]

September 8, 2022
Next Post
Patient Basics: Parkinson’s Disease

Focused ultrasound subthalamotomy revealed improvement in Parkinson’s patients

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

Pembrolizumab linked to longer cancer-free period in advanced colon cancer

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

REGN-COV2 antibody cocktail may reduces viral load in Covid-19 patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options